Efficacy of PD-(L)1 blockade monotherapy compared to PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study

Arielle Elkrief, Joao M. Victor Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Isabel R. Preeshagul, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe Lamberti, Jacklynn V. Egger, Jamie E. Chaft, Charles M. Rudin, Gregory J. Riely, Mark G. Kris, Marc Ladanyi, Yuan Chen, Matthew D. Hellmann, Ronglai Shen, Mark M. Awad, Adam J. Schoenfeld
doi: https://doi.org/10.1101/2022.12.05.22283131

Article Information

doi 
https://doi.org/10.1101/2022.12.05.22283131
History 
  • February 27, 2023.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Arielle Elkrief, MD*,1,2,5,
  2. Joao M. Victor Alessi, MD*,3,
  3. Biagio Ricciuti, MD*,3,
  4. Samantha Brown, MS4,
  5. Hira Rizvi, MS5,
  6. Isabel R. Preeshagul, MD5,
  7. Xinan Wang, PhD, MS7,
  8. Federica Pecci, MD3,
  9. Alessandro Di Federico, MD3,
  10. Giuseppe Lamberti, MD3,
  11. Jacklynn V. Egger, MSc5,
  12. Jamie E. Chaft, MD5,
  13. Charles M. Rudin, MD, PhD5,6,
  14. Gregory J. Riely, MD, PhD5,6,
  15. Mark G. Kris, MD5,6,
  16. Marc Ladanyi, MD1,2,
  17. Yuan Chen, PhD4,
  18. Matthew D. Hellmann, MD5,6,
  19. Ronglai Shen, PhD*,4,
  20. Mark M. Awad, MD, PhD*,3 and
  21. Adam J. Schoenfeld, MD*,5,6,†
  1. 1Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, NY
  2. 2Memorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program, New York, NY
  3. 3Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA
  4. 4Memorial Sloan Kettering Cancer Center, Department of Epidemiology & Biostatistics, New York, NY
  5. 5Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, NY
  6. 6Weill Cornell Medical College, Department of Medicine, New York, NY, USA
  7. 7Harvard T.H. Chan School of Public Health, Harvard Univeristy, Department of Environmental Health, Boston, MA
  1. ↵†Corresponding author:
    Adam J. Schoenfeld, 1275 York Ave, New York, NY 10065, Phone: 6466084042, Email: schoenfa{at}mskcc.org

  1. ↵* Contributed equally

  2. Author contributions: Study conducts and design: JVA, AE, BR, SB, YC, RS, AJS, MMA; data acquisition: JVA, AE, BR, HR, JVE; statistical analysis: JVA, AE, BR, SB, YC, RS; data interpretation: JVA, AE, BR, SB, YC, JVA, AE, BR, SB, YC, RS RS, AJS, MMA; drafting the manuscript or revising it critically: all authors; final approval of the manuscript: all authors.

Back to top
Posted February 27, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Efficacy of PD-(L)1 blockade monotherapy compared to PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study
Arielle Elkrief, Joao M. Victor Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Isabel R. Preeshagul, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe Lamberti, Jacklynn V. Egger, Jamie E. Chaft, Charles M. Rudin, Gregory J. Riely, Mark G. Kris, Marc Ladanyi, Yuan Chen, Matthew D. Hellmann, Ronglai Shen, Mark M. Awad, Adam J. Schoenfeld
medRxiv 2022.12.05.22283131; doi: https://doi.org/10.1101/2022.12.05.22283131
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area